Humacyte, Inc. Warrant
HUMAW
About: Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Employees: 220
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
20% more funds holding
Funds holding: 5 [Q1] → 6 (+1) [Q2]
7% more capital invested
Capital invested by funds: $157K [Q1] → $168K (+$11.2K) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.08% less ownership
Funds ownership: 0.35% [Q1] → 0.28% (-0.08%) [Q2]
Financial journalist opinion
We haven’t received any recent news articles for HUMAW